恩华药业
(002262)
| 流通市值：181.91亿 | | | 总市值：209.05亿 |
| 流通股本：8.84亿 | | | 总股本：10.16亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,610,251,670.32 | 5,911,188,872.18 | 4,470,988,804.69 | 3,010,121,701.84 |
| 营业收入 | 1,610,251,670.32 | 5,911,188,872.18 | 4,470,988,804.69 | 3,010,121,701.84 |
| 二、营业总成本 | 1,251,661,776.48 | 4,768,546,017.03 | 3,262,994,941.65 | 2,233,759,335.62 |
| 营业成本 | 467,498,451.12 | 1,647,615,667.02 | 1,072,024,051.65 | 745,240,827.98 |
| 税金及附加 | 19,423,511 | 74,447,442.9 | 55,676,213.86 | 38,848,380.09 |
| 销售费用 | 534,735,583.98 | 2,114,321,377.81 | 1,413,751,262.79 | 970,836,971.35 |
| 管理费用 | 74,749,188.04 | 263,617,140.82 | 223,590,309.61 | 149,497,318.11 |
| 研发费用 | 156,792,536.9 | 685,535,013.44 | 512,688,666.43 | 335,745,711.7 |
| 财务费用 | -1,537,494.56 | -16,990,624.96 | -14,735,562.69 | -6,409,873.61 |
| 其中:利息费用 | 426,653.1 | 2,438,852.26 | 1,978,782.77 | 1,245,123.48 |
| 其中:利息收入 | 1,529,442.02 | 21,461,971.95 | 17,242,845.09 | 7,667,885.24 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 17,997,689.56 | 61,159,905.52 | 47,009,834.9 | 32,479,568.44 |
| 资产处置收益 | -5,229.56 | 165,788.21 | 36,035.92 | 41,856.14 |
| 资产减值损失(新) | -5,926,389.84 | -30,514,199.68 | -8,321,337.04 | -9,759,417.62 |
| 信用减值损失(新) | -15,464,077.35 | -9,170,427.82 | -10,522,733.85 | -12,275,473.85 |
| 其他收益 | 1,987,770.94 | 34,888,291.15 | 9,109,331.2 | 6,007,398.82 |
| 四、营业利润 | 357,179,657.59 | 1,199,172,212.53 | 1,245,304,994.17 | 792,856,298.15 |
| 加:营业外收入 | 115,237.35 | 3,955,982.36 | 2,101,833.53 | 927,674.44 |
| 减:营业外支出 | 1,571,092.11 | 30,045,843.76 | 13,849,595.69 | 5,379,891.72 |
| 五、利润总额 | 355,723,802.83 | 1,173,082,351.13 | 1,233,557,232.01 | 788,404,080.87 |
| 减:所得税费用 | 38,122,127.18 | 118,180,592.88 | 129,031,463.73 | 88,349,794.88 |
| 六、净利润 | 317,601,675.65 | 1,054,901,758.25 | 1,104,525,768.28 | 700,054,285.99 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 317,601,675.65 | 1,054,901,758.25 | 1,104,525,768.28 | 700,054,285.99 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 317,413,953.67 | 1,057,334,353.51 | 1,106,047,401.4 | 700,494,742.07 |
| 少数股东损益 | 187,721.98 | -2,432,595.26 | -1,521,633.12 | -440,456.08 |
| 扣除非经常损益后的净利润 | 318,264,144.09 | 1,057,820,598.05 | 1,108,638,677.3 | 699,469,413.13 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.31 | 1.05 | 1.09 | 0.69 |
| (二)稀释每股收益 | 0.31 | 1.05 | 1.09 | 0.69 |
| 八、其他综合收益 | - | -1,986,860.16 | - | - |
| 归属于母公司股东的其他综合收益 | - | -1,986,860.16 | - | - |
| 九、综合收益总额 | 317,601,675.65 | 1,052,914,898.09 | 1,104,525,768.28 | 700,054,285.99 |
| 归属于母公司股东的综合收益总额 | 317,413,953.67 | 1,055,347,493.35 | 1,106,047,401.4 | 700,494,742.07 |
| 归属于少数股东的综合收益总额 | 187,721.98 | -2,432,595.26 | -1,521,633.12 | -440,456.08 |
| 公告日期 | 2026-04-18 | 2026-04-18 | 2025-10-25 | 2025-07-30 |
| 审计意见(境内) | | 标准无保留意见 | | |